Skip to main content

Craig R. Jalbert

CEO

Carisma Therapeutics Inc.

Carisma Therapeutics Inc.

Board Member

Carisma Therapeutics Inc.

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Craig R. Jalbert

Craig R. Jalbert is recorded as CEO and Board Member at Carisma Therapeutics Inc.. Carisma Therapeutics Inc. reported in an 8-K filed December 5, 2025 that Craig R. Jalbert was appointed director, effective January 1, 2026. Carisma Therapeutics Inc. reported in an 8-K filed December 5, 2025 that Craig R. Jalbert was appointed Chief Executive Officer, effective January 1, 2026. Carisma Therapeutics Inc. reported in an 8-K filed December 5, 2025 that Craig R. Jalbert was appointed President, Treasurer and Secretary, effective January 1, 2026.

“On December 4, 2025, the Board also appointed Mr. Jalbert as a director, effective as of January 1, 2026.”
Carisma Therapeutics Inc. Form 8-K, filed December 5, 2025 · Read the filing
“On December 4, 2025, the Board appointed Craig R. Jalbert to serve as the Chief Executive Officer, President, Treasurer and Secretary of the Company, effective as of January 1, 2026, to succeed Mr. Kelly and to assist with the Company's remaining wind down activities.”
Carisma Therapeutics Inc. Form 8-K, filed December 5, 2025 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

  • Carisma Therapeutics Inc.

    CEO

    SEC 8-K

    Current

    2026-01-01–present

  • Carisma Therapeutics Inc.

    SEC 8-K

    Current

    2026-01-01–present

  • Carisma Therapeutics Inc.

    Board Member

    SEC 8-K

    Current

    2026-01-01–present

Company network

Recorded roles and call appearances connecting this person to public companies.

Carisma Therapeutics Inc.

Current role

CEO, Board Member

2026-01-01–present

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.